The necessity for clinical reasoning in the era of evidence-based medicine.

Clinical decisions are increasingly driven by evidence-based recommendations of guideline groups, which aim to be based on the highest quality knowledge-randomized clinical trials (RCTs) and meta-analyses. Although RCTs provide the best assessment of the overall value of a therapy, high-quality evidence from RCTs is often incomplete, contradictory, or absent even in areas that have been most exhaustively studied. Moreover, the likelihood of the success or failure of a therapy is not identical in all the individuals treated in any trial because therapy is not the only determinant of outcome. Therefore, the overall results of a trial cannot be assumed to apply to any particular individual, not even someone who corresponds to all the entry criteria for the trial. In addition, the potential for bias due to financial conflicts remains in many guideline groups. Guidelines are key sources of knowledge. Nevertheless, limitations in the extent, quality, generalizability, and transferability of evidence mean that we clinicians must still reason through the best choices for an individual because even in the absence of full and secure knowledge, clinical decisions must still be made. Clinical reasoning is the pragmatic, tried-and-true process of expert clinical problem solving that does value mechanistic reasoning and clinical experience as well as RCTs and observational studies. Clinicians must continue to value clinical reasoning if our aim is the best clinical care for all the individuals we treat.

[1]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[2]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[3]  C. Furberg,et al.  Why guideline-making requires reform. , 2009, JAMA.

[4]  H. Krumholz,et al.  Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. , 2012, Circulation. Cardiovascular quality and outcomes.

[5]  John P A Ioannidis,et al.  Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. , 2011, Journal of clinical epidemiology.

[6]  C. Furberg,et al.  Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. , 2012, Journal of clinical lipidology.

[7]  R. Hayward,et al.  Beyond the Randomized Clinical Trial the Role of Effectiveness Studies in Evaluating Cardiovascular Therapies the Achilles' Heel of Rcts Key Issues in Outcomes Research , 2022 .

[8]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[9]  R. Hegele,et al.  Narrative Review: Statin-Related Myopathy , 2009, Annals of Internal Medicine.

[10]  A. Garg,et al.  Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases , 2013, BMJ.

[11]  J. Kassirer,et al.  Learning Clinical Reasoning , 1991 .

[12]  S. Rogers,et al.  Prevention of infective endocarditis' , 1988, British Dental Journal.

[13]  Ian Graham,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[14]  Richard L Kravitz,et al.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.

[15]  Paul Tibbetts,et al.  Meaning and Action: A Critical History of Pragmatism , 1972 .

[16]  J. Ioannidis Contradicted and Initially Stronger Effects in Highly Cited Clinical Research , 2005 .

[17]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[18]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[19]  F. Gueyffier,et al.  Pharmacotherapy for mild hypertension (Review) , 2012 .

[20]  L. Cohen An Introduction To The Philosophy Of Induction And Probability , 1989 .

[21]  C. Warlow,et al.  Prediction of benefit from carotid endar terectomy in individual patients: a risk-modelling study , 1999, The Lancet.

[22]  M A Gerber,et al.  Prevention of bacterial endocarditis. Recommendations by the American Heart Association. , 1990, JAMA.

[23]  P. Toth Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[24]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[25]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[26]  Pat Croskerry,et al.  From mindless to mindful practice--cognitive bias and clinical decision making. , 2013, The New England journal of medicine.

[27]  The Philosophy of Evidence-Based Medicine , 2013 .

[28]  A. B. Hill Reflections on controlled trial. , 1966, Annals of the rheumatic diseases.

[29]  P. Ridker,et al.  Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. , 2012, Clinical chemistry.

[30]  John P A Ioannidis,et al.  Ensuring the integrity of clinical practice guidelines: a tool for protecting patients , 2013, BMJ : British Medical Journal.

[31]  P. Sipponen,et al.  What fraction of hospital ulcer patients is eligible for prospective drug trials? , 1991, Scandinavian journal of gastroenterology. Supplement.

[32]  Jane M Blazeby,et al.  Challenges in evaluating surgical innovation , 2009, The Lancet.

[33]  R. Califf,et al.  Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.

[34]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[35]  Robert Dufour,et al.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. , 2013, The Canadian journal of cardiology.

[36]  Hill Ab Reflections on controlled trial. , 1966 .

[37]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[38]  Larry M Baddour,et al.  Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Card , 2007, Circulation.

[39]  J. Howick,et al.  Philosophy of Evidence-Based Medicine , 2011 .

[40]  F. Gueyffier,et al.  Pharmacotherapy for mild hypertension. , 2012, The Cochrane database of systematic reviews.